ISR 52
Alternative Names: Inhaled COVID-19 vaccine; ISR-052; ISR-52; SARS-CoV-2 nasal vaccine - Immune System Regulation; SARS-COV-2 vaccine inhaledLatest Information Update: 31 Aug 2023
At a glance
- Originator Immune System Regulation
- Class COVID-19 vaccines; Virus-like particle vaccines
- Mechanism of Action Immunostimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Preclinical COVID 2019 infections
Most Recent Events
- 28 Aug 2023 Immunogenicity data from preclinical trial in COVID-2019 infections released by Immune System Regulation
- 01 Jul 2022 Bangladesh Medical Research Council (BMRC) approves clinical trial application for ISR 52 in COVID-2019
- 21 Feb 2022 Immune System Regulation files clinical trial application with the Bangladesh Medical Research Council (BMRC) for COVID-2019 infections